

24, 2022. Pursuant to Section 60.13 of 36 CFR part 60, comments are being accepted concerning the significance of the nominated properties under the National Register criteria for evaluation.

Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so.

Nominations submitted by State or Tribal Historic Preservation Officers:

Key: State, County, Property Name, Multiple Name (if applicable), Address/Boundary, City, Vicinity, Reference Number.

KENTUCKY

McCracken County

Paducah Northside Historic District, Roughly bounded by North 10th St., Park Ave., North 15th, and Northview St., Paducah, SG100008325

MISSOURI

Jasper County

Joplin East Town Historic District, Roughly bounded by Broadway Langston Hughes, Landreth Ave., Hill St., and Division Ave, Joplin, SG100008307

NEBRASKA

Colfax County

Merchant Park, (New Deal Work Relief Projects in Nebraska MPS), Corner of Higgins Dr. and Adams St., Schuyler, MP10000831

Douglas County

Stephenson and Williams Livery, (Warehouses in Omaha MPS), 1114 Florence Blvd., Omaha, MP100008314
Florence Commercial Historic District, (Streetcar-Era Commercial Development in Omaha, Nebraska MPS), 8500–8702 North 30th St., Omaha, MP100008315
Clifton Hill Commercial Historic District, (Streetcar-Era Commercial Development in Omaha, Nebraska MPS), 1900–2200 blks. Military Ave., Omaha, MP100008316

NEW YORK

Columbia County

Red Rock Schoolhouse, 459 Cty. Rd. 24, Red Rock, SG100008311, Muldor-Miller House, (Claverack MPS), 571 NY 23B, Claverack, MP100008312

Monroe County

Hickey-Freeman Company Building, 1155 North Clinton Ave., 24 Morrill St., and 313 Ave. D, Rochester, SG100008310
Crosman Terrace Historic District, 21 to 188 Crosman Terr., Rochester, SG100008317

Montgomery County

Fort Plain Historic District (Boundary Increase), Portions of Abbott, Canal, Hancock, Beck, Clyde, Douglas, Edwards, Erie, Garfield, Hancock, Henry, Herkimer, High, Main, Reid, River, Roof, State, Wagner, Webster, Willett, and Witter Sts., Clark, Clinton, Gilbert, Silk, and Waddell Aves., Fort Plain, BC100008321

Ontario County

Bristol Center Methodist Episcopal Church, 4471 NY 64, Bristol vicinity, SG100008319

Wyoming County

Perry Village Hall, 46 North Main St., Perry, SG100008318

OREGON

Clatsop County

Cahill-Nordstrom Farm, 85926 Cahill Rd., Clatskanie vicinity, SG100008331

Marion County

Salem Civic Center Historic District, 555 Liberty St. SE, Salem, SG100008330

Multnomah County

Carey, Judge Charles Henry and Mary Bidwell, House, 1950 South Carey Ln., Portland, SG100008329

Polk County

Dallas Cinema, 166 SE Mill St., Dallas, SG100008328

VIRGINIA

Nelson County

Blue Ridge Tunnel, 215 Afton Depot Ln., Afton vicinity, SG100008324

Virginia Beach Independent City

Blue Marlin Lodge, (Virginia Beach Oceanfront Resort Motels and Hotels, 1955–1970 MPS), 2411 Pacific Ave., Virginia Beach, MP100008322
Crest Kitchenette Motel, (Virginia Beach Oceanfront Resort Motels and Hotels, 1955–1970 MPS), 3614 Atlantic Ave., Virginia Beach, MP100008323

Additional documentation has been received for the following resources:

ARKANSAS

Monroe County

La Belle House (Additional Documentation), (Thompson, Charles L., Design Collection TR), 312 New York Ave., Brinkley, AD82000866

NEW YORK

Montgomery County

Fort Plain Historic District (Additional Documentation), Portions of Abbott, Canal, Hancock, Beck, Clyde, Douglas, Edwards, Erie, Garfield, Hancock, Henry, Herkimer, High, Main, Reid, River, Roof, State, Wagner, Webster, Willett, and Witter Sts., Clark, Clinton, Gilbert, Silk, and Waddell Aves., Fort Plain, AD12000510

Authority: Section 60.13 of 36 CFR part 60.

Dated: September 28, 2022.

Sherry A. Frear,

*Chief, National Register of Historic Places/
National Historic Landmarks Program.*

[FR Doc. 2022–21859 Filed 10–6–22; 8:45 am]

BILLING CODE 4312–52–P

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337–TA–1236]

Certain Polycrystalline Diamond Compacts and Articles Containing Same; Notice of the Commission's Final Determination Finding No Violation of Section 337; Termination of the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

SUMMARY: Notice is hereby given that the U.S. International Trade Commission has determined to find no violation of section 337 of the Tariff Act of 1930, as amended, in this investigation. The investigation is terminated in its entirety.

FOR FURTHER INFORMATION CONTACT:

Cathy Chen, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone 202–205–2392. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at <https://www.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on (202) 205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on December 29, 2020, based on a complaint filed by US Synthetic Corporation (“USS”) of Orem, Utah. 85 FR 85661 (Dec. 29, 2020). The complaint alleged violations of section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain polycrystalline diamond compacts and articles containing same by reason of infringement of certain claims of U.S.

Patent No. 10,507,565 (“the ‘565 patent”); U.S. Patent No. 10,508,502 (“the ‘502 patent”); U.S. Patent No. 8,616,306 (“the ‘306 patent”); U.S. Patent No. 9,932,274 (“the ‘274 patent”); and U.S. Patent No. 9,315,881 (“the ‘881 patent”). *Id.* The complaint further alleged that an industry in the United States exists as required by section 337. *Id.* The notice of investigation named as respondents: SF Diamond Co., Ltd., and SF Diamond USA, Inc. (collectively, “SF Diamond”); Element Six Abrasives Holdings Ltd., Element Six Global Innovation Centre, Element Six GmbH, Element Six Limited, Element Six Production (Pty) Limited, Element Six Hard Materials (Wuxi) Co. Limited, Element Six Trading (Shanghai) Co., Element Six Technologies US Corporation, Element Six US Corporation, ServSix US, and Synergy Materials Technology Limited (collectively, “Element Six”); Iljin Diamond Co., Ltd., Iljin Holdings Co., Ltd., Iljin USA Inc., Iljin Europe GmbH, Iljin Japan Co., and Ltd., Iljin China Co., Ltd. (collectively, “Iljin”); Henan Jingrui New Material Technology Co., Ltd. (“Jingrui”); Zhenzghou New Asia Superhard Materials Composite Co., Ltd., and International Diamond Services, Inc. (collectively, “New Asia/IDS”); CR Gems Superabrasives Co., Ltd. (“CR Gems”); FIDC Beijing Fortune International Diamond (“FIDC”); Fujian Wanlong Superhard Material Technology Co., Ltd. (“Wanlong”); Zhujau Juxin Technology (“Juxin”);¹ and Shenzhen Haimingrun Superhard Materials Co., Ltd. (“Haimingrun”) (together, “the Respondents”). *Id.* at 85662. The Office of Unfair Import Investigations did not participate in the investigation. *Id.*

USS moved to terminate the investigation as to Element Six and FIDC over the course of the investigation. All of the motions were granted by non-final initial determinations (“ID”), and the Commission did not review them. *See* Order Nos. 6 (Feb. 1, 2021), 8 (Feb. 8, 2021), 10 (Feb. 24, 2021), and 16 (Apr. 1, 2021). Thus, the only remaining respondents are Iljin, SF Diamond, New Asia/IDS, Haimingrun, Juxin, CR Gems, Jingrui, and Wanlong.

USS also moved for partial termination of the investigation with respect to certain asserted patents and claims. All the motions were granted by non-final IDs, and the Commission did not review them. *See* Order Nos. 26 (Jul.

14, 2021), 32 (Aug. 9, 2021), and 57 (Oct. 19, 2021). As such, the ‘274 and ‘881 patents have been terminated from the investigation. Claims 1, 2, 4, 6, and 18 of the ‘565 patent; claims 1, 2, 11, 15, and 21 of the ‘502 patent; and claim 15 of the ‘306 patent remain in this investigation (collectively, “the Asserted Patents”).

On April 27, 2021, a technology tutorial and *Markman* hearing was held. On May 24, 2021, Order No. 23 issued, which construed certain claim terms of the patents at issue. An evidentiary hearing took place during the week of October 18–22, 2021.

On March 3, 2022, the administrative law judge (“ALJ”) issued his final ID, finding no violation of section 337 by Respondents. Specifically, the ID found at least one accused product infringes all asserted claims of the Asserted Patents, but those claims are invalid under 35 U.S.C. 101 and/or 102. The ID also found that Complainant has shown that the domestic industry requirement has been satisfied with respect to the Asserted Patents. Complainant and Respondents filed separate petitions for review and responses to the petitions for review. On March 31, 2022, Iljin submitted a public interest statement.

On May 9, 2022, the Commission determined to review the ID in part. 87 FR 29375–377 (May 13, 2022). Specifically, the Commission determined to review: (1) the ID’s finding that the asserted claims are invalid under 35 U.S.C. 101; (2) the ID’s finding that the asserted claims of the ‘565 patent are not entitled to an earlier priority date and, thus, they are invalid as anticipated by the sale of the CT–57 product; (3) the ID’s finding that the Mercury product anticipates claims 1 and 2 of the ‘565 patent and claims 1 and 11 of the ‘502 patent; (4) the ID’s finding that Respondents did not prove that the asserted claims are not enabled; and (5) the ID’s findings regarding the economic prong of the domestic industry requirement (including the ruling allowing USS to supplement its domestic industry contentions with a revenue-based allocation method). The Commission determined not to review any other findings presented in the ID, including the ID’s finding of no violation of section 337 with respect to the ‘306 patent. The Commission requested briefing from the parties on certain issues under review and on remedy, the public interest, and bonding. Complainant and Respondents filed their opening written submissions on May 23, 2022, and their responsive written submissions on May 31, 2022. The Commission did not receive public comments from the public on public

interest issues raised by the ALJ’s recommended relief.

Having reviewed the record of the investigation, including the final ID and the parties’ submissions, the Commission has found no violation of section 337 as to claims 1, 2, 4, 6, and 18 of the ‘565 patent and claims 1, 2, 11, 15, and 21 of the ‘502 patent. Specifically, the Commission affirms with modifications the ID’s finding that the asserted claims of the ‘565 patent are not entitled to an earlier priority date and, thus, the claims are anticipated by the prior art CT–57. The Commission reverses the ID’s finding that the Mercury PDC, manufactured by Diamond Innovations, Inc., anticipates claims 1 and 2 of the ‘565 patent and claims 1 and 11 of the ‘502 patent. The Commission affirms with modifications the ID’s finding that Respondents have not proven that the asserted claims of the ‘502, ‘565, and ‘306 patents are not enabled. Having affirmed the ID’s findings that the asserted claims are invalid, the Commission has determined to take no position on the economic prong of the domestic industry requirement.

Commissioner Schmidlein joins the Commission’s decision affirming the ID’s section 102 findings as modified in the Majority opinion but dissents from the Majority’s decision to affirm the ID’s section 101 findings as explained in her dissenting views. She would also affirm with modifications the ID’s conclusion that USS established the economic prong of the domestic industry requirement for the ‘565 patent and the ‘502 patent under subsections (A), (B), and (C) of section 337(a)(3). Accordingly, she would find a violation based on infringement of claims 1, 2, 11, 15, and 21 of the ‘502 patent.

The investigation is terminated with a finding of no violation. The Commission’s reasoning in support of its determinations is set forth more fully in its opinion issued concurrently herewith.

The Commission vote for this determination took place on October 3, 2022.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in Part 210 of the Commission’s Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

¹ On February 8, 2021, Guangdong Juxin Materials Technology Co., Inc. was substituted in place of Zhuhai Juxin Technology. *See* Order No. 8 (Feb. 8, 2021).

Issued: October 3, 2022.

Katherine Hiner,

Acting Secretary to the Commission.

[FR Doc. 2022–21828 Filed 10–6–22; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1073]

Bulk Manufacturer of Controlled Substances Application: Cambridge Isotope Laboratories Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Cambridge Isotope Laboratories, has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before December 6, 2022. Such persons may also file a written request for a hearing on the application on or before December 6, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on July 18, 2022, Cambridge Isotope Laboratories, Inc., 50 Frontage Road Andover, Massachusetts 01810–5413, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Tetrahydrocannabinols	7370	I

The company plans to synthetically bulk manufacture the controlled substance Tetrahydrocannabinols to produce analytical standards for distribution to its customers. No other activities for these drug codes are authorized for this registration.

Kristi O'Malley,

Assistant Administrator.

[FR Doc. 2022–21923 Filed 10–6–22; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1074]

Importer of Controlled Substances Application: Cardinal Health, DBA Specialty Pharmaceutical Service

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Cardinal Health, DBA Specialty Pharmaceutical Service has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before November 7, 2022. Such persons may also file a written request for a hearing on the application on or before November 7, 2022.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to <https://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on <https://www.regulations.gov>. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to:

(1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on July 25, 2022, Cardinal Health, DBA Specialty Pharmaceutical Service, 15 Ingram Boulevard, La Vergne, Tennessee 37086–3630, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Nabilone	7379	II

The company plans to import the above controlled substance in finished dosage form for distribution to licensed registrants for the purpose of medical use only. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2).

Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Kristi O'Malley,

Assistant Administrator.

[FR Doc. 2022–21924 Filed 10–6–22; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1071]

Importer of Controlled Substances Application: Fresenius Kabi USA, LLC

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Fresenius Kabi USA, LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit